The initial success of Sildenafil undeniably transformed the pharmaceutical landscape, but placing funds in companies primarily reliant on unbranded versions presents a challenging picture. Despite early earnings were significant, the expiration of patents and the emergence of discounted alternatives have diminished the customer base. Consequently,